Pancholi, S., Leal, M. F., Ribas, R., Simigdala, N., Schuster, E., Chateau-Joubert, S., . . . Martin, L. (2020). Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. BMC.
Chicago Style (17th ed.) CitationPancholi, Sunil, et al. Correction to: Combination of MTORC1/2 Inhibitor Vistusertib Plus Fulvestrant in Vitro and in Vivo Targets Oestrogen Receptor-positive Endocrine-resistant Breast Cancer. BMC, 2020.
MLA (8th ed.) CitationPancholi, Sunil, et al. Correction to: Combination of MTORC1/2 Inhibitor Vistusertib Plus Fulvestrant in Vitro and in Vivo Targets Oestrogen Receptor-positive Endocrine-resistant Breast Cancer. BMC, 2020.
Warning: These citations may not always be 100% accurate.